Advocating to remove non-payer discounts from the ASP calculation for Medicare Part B Promoting a resilient pharmaceutical supply chain Advocating to amend Hatch-Waxman to limit brand companies from serially suing generic companies over the same molecule. issues related to generic and biosimilar access
Source-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- Not reported
- Expenses
- $140,000.00
- Registrant
- SANDOZ INC
- Client
- SANDOZ INC
- Filing UUID
- 68b10726-34e9-4c72-af67-7b84886a457f
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.